Full Press Release Details
Jaguar Health and its Subsidiary, Napo
Enter Accounts Receivable Purchase Agreement with Oasis
April 2020 sales of Mytesi
generate gross accounts receivable of $2,753,639
SAN FRANCISCO, CA / May 13, 2020 / Jaguar Health, Inc.
(NASDAQ: JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., (collectively, the "Company")
have jointly entered into an accounts receivable purchase agreement with Oasis Capital, LLC ("Oasis") pursuant to which
Oasis has initially agreed to purchase all of the Company's accounts receivable related to the April 2020 sales of the Company's
Mytesi drug product to Cardinal Health, Inc. (the "April 2020 Accounts Receivable"). The April 2020
Accounts Receivable have a gross value of $2,753,639.
"We are pleased to enter into this agreement with Oasis,
as it supports our strategy of bringing in non-dilutive capital as we continue to focus on our new, recently announced enhanced
market access strategy and work to become a stable, cash flow positive business supported primarily by growth in Mytesi sales,"
said Lisa Conte, Jaguar's president and CEO.
Per the terms of the agreement, Oasis will receive a fee of
5.45% (the "Fee") of the $2,753,639 April 2020 Accounts Receivable following their purchase of the April 2020 Accounts
Receivable for $1,032,000 (the "Purchase Price"). Oasis will return to the Company within five days any amount that
exceeds the sum of the Purchase Price and the Fee. As with all Mytesi gross sales, the April 2020 Accounts Receivable will be reduced
by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical trends to determine net sales.
Under the agreement, Oasis is entitled to a one-time transaction
fee of $25,000 and may be entitled to additional transaction fees to the extent Oasis purchases additional accounts receivable
under the agreement, which fees will not exceed $5,000 per transaction.
The initial term of the agreement is one year, which will automatically
renew for successive one-year periods unless notice of non-renewal is provided by the Company at least 30 days prior to the expiration
of a term. Notwithstanding the foregoing, either Oasis or the Company may terminate the agreement on 60 days' prior written
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company
focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly owned subsidiary, Napo
Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global
marketplace from plants used traditionally in rainforest areas. Our Mytesi (crofelemer) product is approved by
the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please visit jaguar.health.
For more information about Napo, visit napopharma.com.
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic
relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the
treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are
not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease
may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory
tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer,
the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal
Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure
a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements." These include statements regarding any possible future purchases of Company accounts receivables by Oasis. In
some cases, you can identify forward-looking statements by terms such as "may," "will," "should,"
"expect," "plan," "aim," "anticipate," "could," "intend,"
"target," "project," "contemplate," "believe," "estimate," "predict,"
"potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking
statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations
and projections about future events. These forward-looking statements speak only as of the date of this release and are subject
to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond
Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.